Antibiofilm Activity and Synergistic Inhibition of Staphylococcus aureus Biofilms by Bactericidal Protein P128 in Combination with Antibiotics.
P128 is an antistaphylococcal protein, comprising a cell wall-degrading enzymatic region and a Staphylococcus-specific binding region, which possesses specific and potent bactericidal activity against sensitive and drug-resistant strains of Staphylococcus aureus To explore P128's ability to kill S. aureus in a range of environments relevant to clinical infection, we investigated the anti-S. aureus activity of P128 alone and in combination with standard-of-care antibiotics on planktonic and biofilm-embedded cells. P128 was found to have potent antibiofilm activity on preformed S. aureus biofilms as detected by CFU reduction and a colorimetric minimum biofilm inhibitory concentration (MBIC) assay. Scanning electron microscopic images of biofilms formed on the surfaces of microtiter plates and on catheters showed that P128 at low concentrations could destroy the biofilm structure and lyse the cells. When it was tested in combination with antibiotics which are known to be poor inhibitors of S. aureus in biofilms, such as vancomycin, gentamicin, ciprofloxacin, linezolid, and daptomycin, P128 showed highly synergistic antibiofilm activity that resulted in much reduced MBIC values for P128 and the individual antibiotics. The synergistic effect was seen for both sensitive and resistant isolates of S. aureus Additionally, in an in vitro mixed-biofilm model mimicking the wound infection environment, P128 was able to prevent biofilm formation by virtue of its anti-Staphylococcus activity. The potent S. aureus biofilm-inhibiting activity of P128 both alone and in combination with antibiotics is an encouraging sign for the development of P128 for treatment of complicated S. aureus infections involving biofilms.
GangaGen Biotechnologies Pvt. Ltd., Yeshwantpur, Bangalore, India.
Sandhya
S
Nair
GangaGen Biotechnologies Pvt. Ltd., Yeshwantpur, Bangalore, India.
Srividya
S
Desai
GangaGen Biotechnologies Pvt. Ltd., Yeshwantpur, Bangalore, India.
Nethravathi
N
Poonacha
GangaGen Biotechnologies Pvt. Ltd., Yeshwantpur, Bangalore, India.
Aradhana
A
Vipra
GangaGen Biotechnologies Pvt. Ltd., Yeshwantpur, Bangalore, India umender@gangagen.com.
Umender
U
Sharma
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D002939:Ciprofloxacin / Q000494:pharmacology; D017576:Daptomycin / Q000494:pharmacology; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial; D005839:Gentamicins / Q000494:pharmacology; D000069349:Linezolid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008855:Microscopy, Electron, Scanning; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005839:Gentamicins; C577473:P128 antistaphylococcal chimeric protein; D011993:Recombinant Fusion Proteins; D002939:Ciprofloxacin; D014640:Vancomycin; D000069349:Linezolid; D017576:Daptomycin
BMC Microbiol. 2012 Mar 22;12:41
22439788
BMC Microbiol. 2011 Oct 11;11:226
21985151
Pathog Dis. 2014 Apr;70(3):231-9
24453168
Pol J Microbiol. 2014;63(2):137-45
25115107
Science. 2011 Nov 18;334(6058):982-6
22096200
Antimicrob Agents Chemother. 2003 Nov;47(11):3407-14
14576095
J Infect Dis. 2014 May 1;209(9):1469-78
24286983
FEMS Immunol Med Microbiol. 2010 Aug;59(3):324-36
20602635
Clin Microbiol Infect. 2013 Feb;19(2):107-12
22925473
Plast Reconstr Surg. 2013 Feb;131(2):225-234
23357984
Int Forum Allergy Rhinol. 2016 Apr;6(4):349-55
26678532
J Wound Care. 2009 Dec;18(12):508, 510-12
20081576
PLoS One. 2013 Jul 02;8(7):e68053
23844154
Virulence. 2011 Sep-Oct;2(5):445-59
21921685
Br J Pharmacol. 2012 Feb;165(4):845-57
21864314
Bacteriophage. 2015 Jun 23;5(3):e1062590
26442196
PLoS One. 2015 Sep 23;10(9):e0138895
26398276
J Antimicrob Chemother. 2011 May;66(5):1057-60
21393156
Sci Rep. 2016 Jul 07;6:29344
27385518
Wound Repair Regen. 2008 Nov-Dec;16(6):805-13
19128252
Science. 2001 Dec 7;294(5549):2170-2
11739958
Antimicrob Agents Chemother. 2010 Apr;54(4):1603-12
20086153
Front Cell Infect Microbiol. 2015 Jan 28;5:1
25674541
Microbiology (Reading). 2014 Oct;160(Pt 10):2157-2169
25023246
Trends Microbiol. 2005 Jan;13(1):34-40
15639630
BMC Res Notes. 2012 Jun 08;5:280
22682527
Antimicrob Agents Chemother. 2002 Jun;46(6):2017-20
12019130
Curr Top Microbiol Immunol. 2008;322:207-28
18453278
J Antimicrob Chemother. 2013 Jan;68(1):4-11
22949625
Lancet Infect Dis. 2011 Mar;11(3):208-22
21371655
FEMS Microbiol Lett. 2004 Jan 15;230(1):13-8
14734160
Science. 1999 May 21;284(5418):1318-22
10334980
Clin Microbiol Rev. 2002 Apr;15(2):167-93
11932229
Annu Rev Microbiol. 2003;57:677-701
14527295
J Med Microbiol. 2013 Oct;62(Pt 10):1506-1516
23813275
Microbiol Spectr. 2015 Jun;3(3):
26185072
Curr Top Microbiol Immunol. 2008;322:107-31
18453274